Lantern Pharma Inc. 2023 Q3 Form 10-Q Summary
Business Context and Reporting Period
Lantern Pharma is a clinical-stage biopharmaceutical company using its RADR® artificial intelligence, machine-learning, genomic and biomarker platform to develop targeted oncology therapies. The filing covers the three and nine months ended September 30, 2023, and was filed November 8, 2023.
- Lead programs include LP-300 in a Phase II NSCLC trial, LP-184 and LP-284 in Phase I trials, and a preclinical antibody-drug conjugate program.
- LP-184 CNS and brain-cancer development is conducted through wholly owned subsidiary Starlight Therapeutics under the name STAR-001.
- The company has not received regulatory or marketing approval for any drug candidate and has not generated operating revenue.
Financial Position and Key Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | None reported | None reported |
| Net loss | $3.16 million in 2023; $2.26 million in 2022 | $11.78 million in 2023; $10.88 million in 2022 |
| Operating expenses | $3.52 million in 2023; $2.15 million in 2022 | $13.00 million in 2023; $10.61 million in 2022 |
| Research and development | $2.21 million in 2023; $0.70 million in 2022 | $8.32 million in 2023; $6.35 million in 2022 |
| General and administrative | $1.31 million in 2023; $1.44 million in 2022 | $4.68 million in 2023; $4.26 million in 2022 |
| Net loss per share | $0.29 | $1.08 |
- Cash and cash equivalents were $25.57 million at September 30, 2023, compared with $37.20 million at December 31, 2022.
- Marketable securities were $19.35 million, compared with $17.99 million at year-end 2022. Total cash, cash equivalents and marketable securities were approximately $44.93 million.
- Working capital was approximately $45.17 million, compared with $55.92 million at December 31, 2022.
- Net cash used in operating activities was $10.96 million for the first nine months of 2023, compared with $10.10 million in 2022.
- Net cash used in investing activities was $1.19 million, primarily reflecting purchases of marketable securities. No financing cash flows occurred in 2023.
- The company reported no long-term debt. Total liabilities were $2.36 million, primarily accounts payable, accrued expenses and operating lease liabilities.
- Accumulated deficit was $51.06 million at September 30, 2023, compared with $39.28 million at December 31, 2022.
Material Changes Versus the Prior Comparable Period
- Third-quarter net loss increased 40% to $3.16 million, while nine-month net loss increased 8% to $11.78 million.
- Third-quarter R&D expense increased 215% to $2.21 million; nine-month R&D expense increased 31% to $8.32 million. The increases primarily reflected higher research studies, manufacturing, payroll, consulting and clinical-development activity.
- R&D expense in the 2022 comparison period was reduced by a $935,000 payment from a service provider, making the year-over-year increase less comparable.
- Nine-month G&A expense increased 10% because of higher professional fees, payroll, travel, business development and rent, partly offset by lower insurance and legal costs.
- Interest income increased to $498,000 from $130,000 for the first nine months, and other income, net, improved to $727,000 from a $402,000 expense, reflecting investment income, investment gains and Australian R&D tax incentives.
- Cash and cash equivalents declined by $11.63 million from year-end, while marketable securities increased by $1.36 million. The decrease in available liquidity was primarily driven by operating cash burn and investment activity.
- The company issued 12,000 restricted shares to consultants during the first nine months. At September 30, 2023, 10,869,040 common shares were outstanding, with 177,998 warrants and 1,060,708 options outstanding.
Guidance, Outlook, Risks and Unusual Items
- Management expects significant and increasing operating losses as LP-300, LP-184 and LP-284 clinical programs advance. The filing does not provide quantitative revenue or earnings guidance.
- Management believes existing cash and cash equivalents will fund operating and capital requirements for at least 12 months from the filing date, based on anticipated expenditures and commitments.
- The company expects to require substantial additional funding to complete clinical trials. Potential equity financing could dilute existing stockholders; debt financing could add fixed obligations and restrictive covenants.
- In May and July 2023, the company entered into agreements with Fortrea to provide CRO services for the LP-300 Phase II and LP-184 Phase I trials. Substantial payments are expected over the following 18 to 24 months, including clinical-site and pass-through costs.
- Clinical development remains subject to enrollment, regulatory, manufacturing, competition, safety, efficacy and commercialization risks. The company may delay, reduce or discontinue programs if funding is unavailable.
- Marketable securities had approximately $814,000 of unrealized losses at September 30, 2023. Management did not consider these losses to represent credit losses, but interest-rate changes could affect investment values and income.
- Substantially all cash held at financial institutions exceeded FDIC insurance limits. The company also has foreign-currency exposure through its Australian subsidiary.
- The restricted-cash escrow related to the Allarity asset purchase agreement ended in July 2023, and remaining funds were distributed to the company in August 2023.
- Management reported effective disclosure controls as of September 30, 2023, with no material changes to internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Clinical-trial enrollment, timing, safety and efficacy data for LP-300, LP-184/STAR-001 and LP-284.
- Actual cash runway relative to the company’s projected clinical-trial spending and Fortrea commitments.
- Timing, structure and potential dilution of future capital raises or other financing.
- Whether the RADR® platform produces commercially actionable biomarker results and supports successful regulatory outcomes.
- Future changes in R&D spending, clinical-site obligations, manufacturing costs and marketable-security values.
- Potential adverse outcomes from regulatory review, competition, trial failure, insufficient funding or inability to commercialize any candidate.